Sysmex Corporation ADR (OTCMKTS:SSMXY) Short Interest Down 53.9% in January

Sysmex Corporation ADR (OTCMKTS:SSMXY) saw a significant decrease in short interest during the month of January. As of January 15th, there was short interest totaling 127,705 shares, a decrease of 53.9% from the December 31st total of 277,294 shares. Based on an average daily volume of 698,584 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.0% of the shares of the company are sold short. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 698,584 shares, the days-to-cover ratio is currently 0.2 days.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group raised Sysmex from a “hold” rating to a “buy” rating in a report on Thursday, October 9th. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy”.

Sysmex Stock Performance

OTCMKTS SSMXY opened at $9.50 on Thursday. The firm has a 50-day moving average price of $9.75 and a two-hundred day moving average price of $11.90. Sysmex has a 12-month low of $9.00 and a 12-month high of $19.85. The company has a market capitalization of $5.98 billion, a P/E ratio of 19.00 and a beta of 1.13. The company has a quick ratio of 2.49, a current ratio of 3.34 and a debt-to-equity ratio of 0.11.

Sysmex (OTCMKTS:SSMXY) last announced its earnings results on Wednesday, November 5th. The company reported $0.16 EPS for the quarter, hitting the consensus estimate of $0.16. Sysmex had a net margin of 9.32% and a return on equity of 9.86%. The company had revenue of $826.60 million for the quarter, compared to analysts’ expectations of $880.80 million. Analysts anticipate that Sysmex will post 0.57 earnings per share for the current year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.